Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Finance.
Introduced in Senate
Read twice and referred to the Committee on Finance.
Health
Civil actions and liabilityCorporate finance and managementGovernment information and archivesInflation and pricesMarketing and advertisingPrescription drugsResearch and development
Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
USA116th CongressS-474| Senate
| Updated: 2/13/2019
Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.
Civil actions and liabilityCorporate finance and managementGovernment information and archivesInflation and pricesMarketing and advertisingPrescription drugsResearch and development